Wild poliovirus type 3 (WPV3) has not been seen anywhere since the last case of This report provides estimates for the probabilities of poliovirus elimination in Nigeria given available data as of March 31, 2015. It is based on a model of disease transmission that is built from historical polio incidence rates and is designed to represent the uncertainties in transmission dynamics and poliovirus detection that are fundamental to interpreting long time periods without cases.
Introduction
Since the World Health Assembly announced the intention to eradicate polio worldwide in 1988, all countries except Pakistan, Afghanistan, and Nigeria have certified elimination of all three wild poliovirus (WPV) serotypes at least once [1] . Nigeria may be the next country to achieve wild-type polio elimination. The most recent case of wild-type 1 (WPV1) in Nigeria occurred in July 2014 [2] . The most recent case of wild-type 3 (WPV3) seen globally occurred in Nigeria in November 2012 [1] . Is Nigeria wild-polio-free? Is WPV3 eradicated globally? Furthermore, the last case of WPV1 in Africa occurred in Somalia at the tail end of the Horn of Africa Outbreak in August 2014. Is Africa wild-polio-free?
The primary mechanism for detecting poliovirus in a population is surveillance for paralytic poliomyelitis. The incidence of poliomyelitis is tracked by the acute flaccid paralysis (AFP) surveillance and global polio laboratory network [3, 4] . The certification period to declare that a polio serotype has been eliminated from a previously endemic region with certification-standard surveillance is three or more years without a polio case [5] . This criterion is based on experience with regional elimination [6] and is necessarily long because paralysis due to polio is uncommon. Estimated case-to-infection ratios are 1:200 for wild type 1, 1:1900 for wild type 2, and 1:1150 for wild type 3 [7] .
Previous modeling work has supported that the three year rule of thumb is reasonable, but that more precise estimates of the elimination time depend on the case-to-infection ratio for each serotype and the local conditions leading up to elimination [8, 9] .
Polio elimination in the most challenging settings has been driven by supplemental immunization activities that require extensive resources and prolonged community engagement to be successful [2, 10, 11] . Operational capacity and community engagement can be difficult to maintain for years in the presence of political instability, humanitarian crises, and substantial health care needs unrelated to polio [2, 12] . While it is reasonable to maintain the three year certification period as the gold standard, the operational, humanitarian, and financial requirements support the need for specific, data-driven estimates of the likely period of silent polio persistence.
The need for specific silent duration estimates is especially important in the context of the plan to stop all use of trivalent oral polio vaccine (tOPV) in April 2016 and replace it 2/18 with bivalent OPV (bOPV) containing only serotypes 1 and 3 to prevent the seeding of new type 2 circulating vaccine-derived polio (cVDPV2) outbreaks [13, 14] . cVDPV outbreaks can occur when vaccine strains transmit for sufficient time to allow for genetic reversion of the markers of attenuation [14] . OPV2 is the most common source of cVDPV globally [15] , and Nigeria has had ongoing transmission of cVDPV2 since 2005 [2, 16] . In 2014, cVDPV2
was the dominant cause of poliomyelitis in Nigeria [2] , and this is likely because Nigeria has been primarily using bOPV to drive the successes in WPV control [17, 18] . However, due to expanded use of tOPV from the second half of 2014 [19] , cVDPV2 cases in Nigeria abruptly stopped appearing at the end of November 2014 after producing 30 cases earlier that year [2] . Are the established cVDPV2 lineages gone? Will they be gone before the planned April 2016 tOPV cessation deadline? When is it reasonable for Nigeria to switch from a strategy focused on WPV elimination to one focused on cVDPV2?
To estimate the probabilities of elimination from Nigeria given the data available at the time of preparation, March 31, 2015, I built a model appropriate to answer the question:
how long do we have to wait before a chain of transmission either terminates or produces another case? The model is based on four premises: (1) that elimination only depends on the last few hundred to few thousand infections in a much larger population, (2) that we only need to see one more case to know elimination did not occur, (3) that we do not care where infected people are located because AFP surveillance will find any cases, and (4) that the few remaining pockets of infection have similar transmission dynamics to the many sources of polio cases in the past. The model incorporates both the parametric and stochastic uncertainties that limit our knowledge of polio transmission. It provides estimates of the probability of elimination given no new cases and the time to the next case if elimination does not occur, and the results are appropriate for supporting the rational analyses [20] of planned polio vaccination policies.
Results
The left column of Fig. 1 depicts elimination: it shows the probability by date that each serotype been eliminated if no new cases are detected. The right column depicts case detection: it shows the probability of the time to the next case if elimination does not occur under the assumption that surveillance is of sufficiently high quality that no polio 3/18 cases are missed. The dashed line indicates March 31, 2015. The blue curves provide estimates based on models with mean effective reproductive number equal to 1 (mean growth rate of the number of active infections equal to 0). R eff = 1 is the worst-case scenario because it maximizes the possible duration of silent transmission without elimination. Deviations from this assumption either make elimination easier (R ef f < 1) or make the silent period between cases shorter (R ef f > 1). For WPV1 and WPV3, the green curves provide less conservative estimates based on the assumption that vaccination quality maintains mean R eff < 1 (growth rate < 0) at the level estimated at the time of the last case. For cVDPV2, the green curve assumes that the mean growth rate is held at one standard deviation below zero. Comments below summarize results from the green curves unless otherwise stated. In each panel, the horizontal axis origin is the time of the most recent case, the blue curve shows the worst-case scenario with mean R eff = 1, and the green curve shows a less conservative scenario with mean R eff < 1. For cVDPV2 (C,F), the orange curve depicts an optimistic scenario in which the mean R eff is held at the lowest value ever observed and the standard deviation is reduced to one-fourth of its observed value.
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WPV1. The most recent WPV1 case in Nigeria occurred on July 24, 2014. As of March WPV3. The most recent WPV3 case globally occurred on November 11, 2012 in Nigeria.
As of March 31, 2015, there is a > 99% chance that WPV3 has been eliminated from Nigeria and thus eradicated globally. In the unlikely event WPV3 has not been eradicated, there is a > 99% chance we will see a new case by the end of 2015. The prediction for the probability of cVDPV2 elimination is sensitive to assumptions about future type 2 immunity. The rapid disappearance of cases in late 2014 (from one case every 10 days on average in 2014 to no cases in over 4 months) implies that type 2 immunity is higher in the relevant population than it has been at any time previously, and so models based on historical transmission rates are likely too conservative. As population immunity affects transmission dynamics through herd effects that reduce the force of infection [23] , consider three scenarios for the force of infection in 2015 and beyond:
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• Excellent tOPV coverage (orange): If the recent improvements in tOPV vaccination quality and higher tOPV campaign frequency maintain the mean growth rate at the lowest level observed in any interval for any serotype in the last ten years λ − µ = −9.21 yr −1 (such that mean R ef f ≈ 0.60) and reduce the variability of the growth rate to one-fourth of the historical standard deviation, then there is a 13% chance of elimination by the end of June 2015 and a 99% chance cVDPV2 will be eliminated by April 2016 if no new cases are seen.
• Good tOPV coverage (green): If growth rates persist at one standard deviation below the historical norm but not at unprecedented levels (such that mean R ef f ≈ 0.85), then there is only a 3% chance of elimination by the end of June 2015
and an 83% chance that cVDPV2 will be eliminated by April 2016 if no new cases are seen. The probability of elimination rises to 98% by the end of 2017.
• Historically typical tOPV coverage (blue): If the mean growth rate is zero (R eff = 1), elimination is unlikely with a 1% chance prior to June 2015. The estimated probability of elimination without seeing a case rises to 66% by April 2016, but does not reach 95% until June 2017.
This analysis is focused solely on estimating the elimination probability for established cVDPV2 lineages and does not account for the emergence of new cVDPV2 lineages. In the event of a new emergence, these estimates would remain valid for the current genetic lineages, but additional modeling would be required to produce estimates for any new lineages and cVDPV2 overall.
Discussion
As of March 31, 2014, the model predicts that WPV3 has been eradicated globally and there is an 70% chance that Africa is completely wild-polio free for the first time in history. The above points suggest to this author that it would be reasonable for the polio program in Nigeria to place more emphasis on cVDPV2 prevention by the end of 2015.
However, until the world is wild-polio-free, the risk of the re-importation of WPV1 must be balanced with the risk of ongoing cVDPV2 transmission and new cVDPV emergence.
Furthermore, certification of polio-free status is a stringent goal wiith additional requirements for surveillance and specimen containment [5] , and so these estimates need to be considered in that context. The model was designed to help policymakers manage that balance. Involved parties may use the probabilities over time to weight different scenarios and inform their planning [20] , and the model can be easily extended to consider alternative scenarios about the future dynamics of the force of infection.
If a new case is detected, then these model predictions are no longer valid. However, since the silent periods as of March 31, 2015 are much longer than typical, a new case would likely represent one of two scenarios. It would either be the last orphan case very near elimination, or it will be the first case of a new outbreak for which more cases will shortly follow. In the event another case occurs but is not followed by an outbreak, this 7/18 analysis can be repeated to provide updated estimates. In the event of an outbreak, surveillance sensitivity is not the primary policy concern.
The model assumes that the balance of birth and vaccination maintains stationary dynamics for the force of infection with constant mean infection growth rate and random variability. With additional data about birth demographics and vaccination activities, this model can be extended to include non-random structure in the statistical model of the force of infection. One could inform such models by correlating the apparently random changes in the force of infection with the supplemental vaccination calendar [2, 10, 11, 19] to estimate how future campaigns may affect the force of infection and subsequent probability of elimination.
The model is based solely on AFP surveillance and ignores any role for alternative active surveillance strategies such as environmental surveillance [24] . Certification-quality AFP surveillance provides a representative sample from all populations regardless of location. It is not obvious how to include environmental surveillance (ES) in the model because ES is only sensitive at fixed locations, but the model makes no assumptions about spatial structure. Because ES can dramatically improve the sensitivity in well-characterized populations [24, 25] , the role of ES in certifying elimination warrants further empirical and theoretical study.
Methods
The persistent intervals prior to elimination and the silent periods between cases given no elimination are determined by the force of infection, the case-to-infection ratio for each serotype, the mean infectious duration, and the number of extant infections at the time of the most recent case. In contrast to complex models with many elements that explicitly model assumptions about the influences of demographics, contact patterns, heterogeneous immune states, and vaccination history on transmission [8, 9] , this model reduces all the complexity of transmission into a statistical model for the time-varying force of infection.
This design facilitates efficient marginalization over the substantial uncertainty in transmission dynamics in a manner consistent with the limited available data. The range of the simulated outcomes from the model honestly represents the contributions of both parametric and stochastic uncertainties to the estimates of the probabilities of elimination.
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Dynamical model. The deterministic approximation to the model is given by a single with scraped data from refs. [17, 36] . The remaining data after September 2014 was derived from the weekly tally sheets available at ref. [29] . The paralytic polio cases were re-binned to count the number of cases, C(t), in ∆t = 3 month intervals and the growth rate between intervals was estimated as λ(t + ∆t) − µ = . When there are no cases in an interval, the growth rate was assumed to be the same as in the nearest bin for which there was data (Fig. 2) .
The Note that while the overall case counts vary over time by two orders of magnitude, the reproductive number mean and range are stable. This motivates the assumption that transmission dynamics are stable among the populations that support ongoing transmission even as the number of such populations is lower now than a decade ago. differences by serotype (Fig. 3A) series for the growth rate λ(t) − µ from independent samples for each 3 month interval from the growth rate distribution. The assumption of independence between intervals is justified because weak seasonality has little influence on the interval between cases (Fig. 4 of ref. [9] ). Example trajectories are shown in Fig. 3 . The mean infectious duration was Model of the interval between cases. To model the interval between cases, simulations were initialized at the time of the most recent observed case. I assumed that progression from infection to paralysis can be modeled as a Bernoulli trial with probability p = (case-to-infection). Estimated case-to-infection ratios are 1:200 for WPV1, 1:1150 for WPV3, and 1:1900 for cVDPV2 [7] under the assumption that cVDPV2 has an indistinguishable phenotype from wild type 2 [14] . Accordingly, the probability that infection number N i is the next paralytic case is geometrically distributed,
Initial condition distribution. The interval between the two most recent observed cases provides a target to calibrate the initial prevalence. The range of initial infections was calibrated to match the median interval between cases in the model to the observed interval between the two most recent cases. This is based on the assumption that prior to observing a silent period, the next case interval is expected to be similar to the previous one.
For WPV1, the most recent case occurred on July 24, 2014 and the observed interval to the case prior to it was ∆t c = 58 days earlier [29] . (For comparison, since the start of 2012, the typical interval between WPV1 cases was 5.5 [1, 27] For each µ, gradient descent was used to reduce the absolute difference between the median time to the next case in the model and the target interval to at most one day. The resulting fits of the initial conditions to the median intervals are closely approximated by a simple curve that depends on µ, the case-to-infection ratio for each serotype, the target 12/18 interval between cases, and a factor of order 1:
with f WPV1 = 0.55, f WPV3 = 0.60, and f cVDPV2 = 0.90.
The initial condition curves indicate that at the time of the most recent case, the prevalence of cVDPV2 was approximately 22 times greater than the prevalence of WPV1
and 73 times greater than WPV3 at the times of their most recent cases.
Simulation procedure. The stochastic version of the model was coded in C# and trajectories were simulated using the Gillespie's direct method for time-varying rates [30, 31] . For each run of the model, the parameters µ, λ(t), and the number of infections required to produce the next case were sampled from their distributions, and the simulation was stopped when elimination occurred or the number of infections required to produce a case was reached. For all scenarios, at least 20 000 simulations and up to 200 000 simulations were run to produce Fig. 1 .
Probabilities of elimination and the time to the next case. The probability of elimination without seeing another case was estimated as:
P elimination (t) = n e (t) n e (t) + n p (t) ,
where n e (t) is the number of simulations that eliminate at or before time t and n p (t) is the number of simulations that persist past time t. The probability of the time to the next case given elimination does not occur and given the observed silent period through March 31, 2015 is estimated as the number of simulations that produce a case after March 31, 2015 but at or before time t over the number of simulations that produce a case at any time after March 31, 2015.
